PE20231303A1 - Forma solida de compuesto - Google Patents
Forma solida de compuestoInfo
- Publication number
- PE20231303A1 PE20231303A1 PE2023000209A PE2023000209A PE20231303A1 PE 20231303 A1 PE20231303 A1 PE 20231303A1 PE 2023000209 A PE2023000209 A PE 2023000209A PE 2023000209 A PE2023000209 A PE 2023000209A PE 20231303 A1 PE20231303 A1 PE 20231303A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- formula
- theta
- degrees
- crystalline form
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000007787 solid Substances 0.000 title abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 6
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 abstract 2
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 150000003892 tartrate salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a una forma solida de un compuesto de formula (I) o una sal o solvato del mismo, el cual se caracteriza porque es: a) la forma cristalina A de la base libre del compuesto de formula (I), caracterizado por los datos de difraccion de polvo de rayos X (XRPD) que incluye los siguientes picos: 4.781, 7.361, 7.619, 9.58, 10.54, 10.979, 11.459, 12.34, 12.96, 13.278, 14.678, 17.402, 18.54, 19.26, 19.918, 21.581, 22.26, 22.54, 23.521, 24.217, 24.801, 25.181 y 29.219 grados dos-theta, b) la forma cristalina I de la sal tartrato del compuesto de formula (I), caracterizado por los datos de difraccion de polvo de rayos X (XRPD) que incluye los siguientes picos: 4.627, 10.34, 13.019, 15.76, 16.54, 17.159, 17.981, 18.281, 20.538, 21.2, 21.901, 23.121, 24.721, 25.659, 27.299, 27.541, 29.879, 32.277 y 41.821 grados dos-theta, c) la forma cristalina I de la sal fosfato del compuesto de formula (I), caracterizado por los datos de difraccion de polvo de rayos X (XRPD) que incluye los siguientes picos: 9.121, 10.082, 12.6, 13.76, 14.52, 15.941, 18.581, 19.08, 19.781, 20.581, 22.319, 23.381, 23.818, 24.642, 25.66, 26.537, 28.219, 29.419 y 33.98 grados dos-theta, d) la forma cristalina I de la sal maleato del compuesto de formula (I), caracterizado por los datos de difraccion de polvo de rayos X (XRPD) que incluye los siguientes picos: 6.801, 9.575, 10.32, 13.258, 13.662, 15.041, 15.998, 18.459, 19.761, 20.237, 20.781, 21.498, 21.78, 22.185, 24.12, 25.599, 27.062, 28.203 y 35.258 grados dos-theta, o e) la forma cristalina I de la sal benzoato del compuesto de formula (I), caracterizado por los datos de difraccion de polvo de rayos X (XRPD) que incluye los siguientes picos: 3.981, 6.639, 8.461, 9.6, 12.119, 12.602, 14.52, 15.441, 16.882, 18.12, 18.941, 20.16, 20.639, 51.699, 23.378, 23.719, 24.659, 28.418 y 29.259 grados dos-theta. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son inhibidores de a proteina tirosina cinasa 2 (PTK2 o tambien conocida como FAK), siendo utiles en el tratamiento del cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010768730 | 2020-08-03 | ||
| CN202010837005 | 2020-08-19 | ||
| PCT/CN2021/110069 WO2022028367A1 (zh) | 2020-08-03 | 2021-08-02 | 化合物的固体形式 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231303A1 true PE20231303A1 (es) | 2023-08-24 |
Family
ID=80119956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000209A PE20231303A1 (es) | 2020-08-03 | 2021-08-02 | Forma solida de compuesto |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230278985A1 (es) |
| EP (1) | EP4190774B1 (es) |
| JP (1) | JP2023536491A (es) |
| KR (1) | KR20230048089A (es) |
| CN (1) | CN116096713B (es) |
| AU (1) | AU2021323235A1 (es) |
| BR (1) | BR112023001962A2 (es) |
| CA (1) | CA3188244A1 (es) |
| CL (1) | CL2023000313A1 (es) |
| ES (1) | ES3049298T3 (es) |
| MX (1) | MX2023001418A (es) |
| PE (1) | PE20231303A1 (es) |
| TW (1) | TW202206425A (es) |
| WO (1) | WO2022028367A1 (es) |
| ZA (1) | ZA202301378B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023224815A1 (en) * | 2022-02-28 | 2024-09-26 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Compound as fak inhibitor and use thereof |
| TW202408528A (zh) | 2022-06-24 | 2024-03-01 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
| CN118580221A (zh) * | 2023-03-02 | 2024-09-03 | 应世生物科技(南京)有限公司 | 化合物的固体形式 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| CA2991044C (en) * | 2015-06-29 | 2024-11-19 | Verastem, Inc. | THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE |
| KR102861189B1 (ko) * | 2019-03-28 | 2025-09-16 | 앰플리아 테라퓨틱스 리미티드 | Fak 억제제의 염 및 결정 형태 |
| WO2020202005A1 (en) * | 2019-04-02 | 2020-10-08 | Inxmed (Shanghai) Co., Ltd. | Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors |
| WO2021098679A1 (zh) * | 2019-11-18 | 2021-05-27 | 应世生物科技(南京)有限公司 | Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途 |
| PE20230180A1 (es) * | 2019-11-28 | 2023-02-01 | Inxmed Nanjing Co Ltd | Uso de bi853520 en tratamiento contra el cancer |
| CA3168648A1 (en) * | 2020-01-31 | 2021-08-05 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| AU2021215747A1 (en) * | 2020-02-05 | 2022-08-18 | Inxmed (Nanjing) Co., Ltd. | Combination of BI853520 with chemotherapeutic drugs |
| TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| TW202408528A (zh) * | 2022-06-24 | 2024-03-01 | 大陸商應世生物科技（南京）有限公司 | 治療腫瘤的藥物組合及用途 |
-
2021
- 2021-08-02 CN CN202180058118.8A patent/CN116096713B/zh active Active
- 2021-08-02 PE PE2023000209A patent/PE20231303A1/es unknown
- 2021-08-02 WO PCT/CN2021/110069 patent/WO2022028367A1/zh not_active Ceased
- 2021-08-02 ES ES21852825T patent/ES3049298T3/es active Active
- 2021-08-02 MX MX2023001418A patent/MX2023001418A/es unknown
- 2021-08-02 KR KR1020237007453A patent/KR20230048089A/ko active Pending
- 2021-08-02 TW TW110128408A patent/TW202206425A/zh unknown
- 2021-08-02 BR BR112023001962A patent/BR112023001962A2/pt unknown
- 2021-08-02 AU AU2021323235A patent/AU2021323235A1/en active Pending
- 2021-08-02 EP EP21852825.5A patent/EP4190774B1/en active Active
- 2021-08-02 CA CA3188244A patent/CA3188244A1/en active Pending
- 2021-08-02 JP JP2023507466A patent/JP2023536491A/ja active Pending
- 2021-08-02 US US18/019,747 patent/US20230278985A1/en not_active Abandoned
-
2023
- 2023-02-01 CL CL2023000313A patent/CL2023000313A1/es unknown
- 2023-02-02 ZA ZA2023/01378A patent/ZA202301378B/en unknown
- 2023-07-05 US US18/347,335 patent/US11999719B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023001962A2 (pt) | 2023-04-11 |
| US20230278985A1 (en) | 2023-09-07 |
| US20240051942A1 (en) | 2024-02-15 |
| MX2023001418A (es) | 2023-04-10 |
| EP4190774B1 (en) | 2025-10-01 |
| CL2023000313A1 (es) | 2023-07-28 |
| CN116096713B (zh) | 2025-04-29 |
| EP4190774A4 (en) | 2024-01-17 |
| ZA202301378B (en) | 2025-05-28 |
| EP4190774A1 (en) | 2023-06-07 |
| TW202206425A (zh) | 2022-02-16 |
| AU2021323235A1 (en) | 2023-03-02 |
| WO2022028367A1 (zh) | 2022-02-10 |
| ES3049298T3 (en) | 2025-12-16 |
| KR20230048089A (ko) | 2023-04-10 |
| JP2023536491A (ja) | 2023-08-25 |
| CN116096713A (zh) | 2023-05-09 |
| CA3188244A1 (en) | 2022-02-10 |
| US11999719B2 (en) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231303A1 (es) | Forma solida de compuesto | |
| PE20210392A1 (es) | Compuestos utiles para inhibir a cdk7 | |
| CY1123353T1 (el) | Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης | |
| ZA202102999B (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| MX374513B (es) | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. | |
| CU20200070A7 (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina | |
| CY1120179T1 (el) | Ετεροκυκλικη ενωση που περιεχει αζωτο ή αλας αυτης | |
| UY31072A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| NZ711376A (en) | Heteroaryl compounds and uses thereof | |
| EA201000886A1 (ru) | Органические соединения | |
| EA202090413A1 (ru) | Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы | |
| MX2018011792A (es) | Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam). | |
| PH12016501048A1 (en) | Piperidine derivatives as mdm2 inhibitors for the treatment of cancer | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| EA201892436A1 (ru) | Пиримидиновые соединения в качестве ингибиторов jak киназы | |
| EA201001772A1 (ru) | Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| PE20210002A1 (es) | Sales de derivados de pirrolotriazina utiles como inhibidores tam |